Health enSuite Insomnia: an App-based Treatment for Adult Chronic Insomnia
- Conditions
- Insomnia
- Registration Number
- NCT04962087
- Lead Sponsor
- IWK Health Centre
- Brief Summary
This project consists of a randomized controlled trial. The objective of this trial is to test the effectiveness of an app-based cognitive behavioral program for insomnia (Health enSuite: Insomnia) in reducing insomnia symptoms.
- Detailed Description
Insomnia or insufficient sleep is one of the most prevalent public health issues. Nearly 1 in 4 Canadians over the age of 18 years report having difficulty falling asleep or maintaining sleep, the majority of whom have experienced these insomnia symptoms for more than a year. Chronic insomnia is characterized by one or more of the following symptoms occurring for at least three nights per week for at least 3 months: difficulty falling asleep, trouble maintaining sleep, difficulty in getting back to sleep, poor quality of sleep, and waking up too early the next morning. These symptoms persist despite adequate opportunity for sleep and are accompanied by significant impairments in daytime functioning.
Cognitive behavioral therapy for insomnia (CBT-I) is a multi-component intervention approach that is recommended as the first line of treatment for patients with persistent insomnia. It targets beliefs, thoughts, and expectations related to sleep as well as behavioral factors that result in sleep loss (sleep schedules, caffeine intake prior to bedtime, bright light in bedroom). These interventions have been found to improve the quality and the duration of sleep and improve daytime functioning. Despite the efficacy of CBT-I programs, they are not readily available to most patients. Therefore, our goal is to develop a CBT-I program that can be delivered through an internet connected phone, tablet, or computer and provide effective treatment to a wide range of people with chronic insomnia. Given that many individuals seek help for sleep problems online or face barriers accessing in-person care, internet-based CBT-I offers a scalable and accessible solution for those experiencing chronic insomnia.
Sleep medications are commonly used to manage insomnia symptoms. These include benzodiazepines such as temazepam and non-benzodiazepines like zopiclone, zolpidem, and zaleplon (often referred to as "Z drugs"). While these benzodiazepine receptor agonists (BZRAs) can be effective in the short term, long-term use is associated with diminishing benefits and potential risks, such as side effects, dependence, and-particularly in older adults-falls and cognitive impairment. Given these concerns, there is growing recognition of the importance of expanding access to non-pharmacological, evidence-based treatments for insomnia. Cognitive behavioral therapy for insomnia (CBT-I) is one such approach, but it remains underutilized due to limited availability. A widely accessible, app-based CBT-I program has the potential to fill this gap and offer a safer, long-term solution for individuals struggling with chronic insomnia.
This project consists of a randomized controlled trial. The objective of this trial is to test the effectiveness of an app-based cognitive behavioral program for insomnia (Health enSuite: Insomnia) in reducing insomnia symptoms.
The objectives will be to assess the effectiveness of CBT-I delivered through the Health enSuite app in:
* Reducing the severity of insomnia symptoms (primary outcome)
* Increasing sleep efficiency and total sleep time (secondary outcomes)
* Reducing sleep onset latency, time in bed, and the duration and frequency of awakenings at night (secondary outcomes)
* Reducing symptoms of psychological distress, anxiety, and depression (secondary outcomes) User engagement and satisfaction with Health enSuite: Insomnia will also be evaluated to inform subsequent efforts to make this program available on a larger scale.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 415
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in Insomnia Severity Index (ISI) Score Baseline assessment, 2 months post-randomization, 5 months post-randomization The ISI is a 7-item questionnaire measuring insomnia severity, dissatisfaction with sleep, interference with daily functioning, and daytime impairment. Scores range from 0-28, with higher scores indicating more severe insomnia.
- Secondary Outcome Measures
Name Time Method Change in Depression, Anxiety, and Stress Scores (DASS-21) Baseline assessment, 2 months post-randomization, 5 months post-randomization The DASS-21 is a 21-item questionnaire measuring psychological distress across three subscales: depression, anxiety, and stress. Each item is scored 0-3, and higher scores indicate greater distress.
Change in Sleep Efficiency Baseline assessment, 2 months post-randomization, 5 months post-randomization Sleep efficiency will be calculated from sleep diary data as the ratio of total sleep time to time in bed (percentage).
Change in Total Sleep Time Baseline assessment, 2 months post-randomization, 5 months post-randomization Total sleep time in hours will be calculated from daily sleep diaries. Unit of Measure: Hours of sleep (hours/night).
Change in Sleep Onset Latency Baseline assessment, 2 months post-randomization, 5 months post-randomization Sleep onset latency (minutes taken to fall asleep) will be measured via sleep diary.
Unit of Measure: Minutes.Change in Wake After Sleep Onset (WASO) Baseline assessment, 2 months post-randomization, 5 months post-randomization WASO (total time awake after initially falling asleep) will be recorded via sleep diary.
Unit of Measure: Minutes.
Trial Locations
- Locations (1)
Centre for Research in Family Health, IWK Health
🇨🇦Halifax, Nova Scotia, Canada
Centre for Research in Family Health, IWK Health🇨🇦Halifax, Nova Scotia, CanadaPatrick McGrath, PhDContact